C5 inhibitors were associated with significantly lower mortality (17% vs. 61.9%, p=0.03) in patients with cancer-associated and chemotherapy-induced thrombotic microangiopathy.
Does severe renal dysfunction alter plasma levels of DNA-reactive fPt after oxaliplatin administration in rats and hemodialysis patients?
The kidney has a limited effect on the plasma levels of DNA-reactive fPt after oxaliplatin administration, suggesting severe renal dysfunction may not significantly alter its elimination.
Absolute Event Rate: 0% vs 0%
Among patients treated with C5 inhibitors, mortality was lower (17% vs. 61.9%,p=0.03).Overall, 56.3% of patients died, with no difference between CA-and CH-TMA.Leading causes of death were cancer progression (59.3%), infection (22.2%), and TMA (7.4%).Conclusion: CA-TMA and CH-TMA differ in cancer type and clinical presentation.CH-TMA was mainly associated with GI malignancies and showed more severe renal involvement but better renal recovery.Nearly one-fifth required dialysis.C5 inhibition may benefit in selected CH-TMA patients.Both CA-and CH-TMA carried a poor prognosis, with mortality approaching 60%.I have potential conflict of interest to disclose.I have an honorarium with Alexion.I did not use generative AI and AI-assisted technologies in the writing process.
Nakagawa et al. (Wed,) reported a other. C5 inhibitors were associated with significantly lower mortality (17% vs. 61.9%, p=0.03) in patients with cancer-associated and chemotherapy-induced thrombotic microangiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: